case_images: PMC10601777_01
case_images: a Timeline of events in Case 1. b Timeline of events in Case 2.
case_images: cro-2023-0016-0001-534150_F01.jpg
case_images: PMC10601777_02_cro-2023-0016-0001-534150_F01.jpg
case_images: F1
case_images: Since April 2022, he experienced nocturnal cough, dyspnea, and wheezing (Fig. 1b).
case_images: Chest computed tomography (CT) findings of case 1, after 3 months (April 2022) (a), and 5 months (June 2022) (b) of enfortumab vedotin treatment. CT revealed minor ground-glass opacities.
case_images: cro-2023-0016-0001-534150_F02.jpg
case_images: PMC10601777_01_cro-2023-0016-0001-534150_F02.jpg
case_images: F2
case_images: On June 30, 2022, computed tomography revealed numerous ground-glass opacities in both the lungs (Fig. 2).
case_images: A decrease in eosinophil count is observed after starting asthma treatment in the patient in case 1. BUD/FL + PSL, budesonide/formoterol fumarate + prednisolone.
case_images: cro-2023-0016-0001-534150_F03.jpg
case_images: PMC10601777_01_cro-2023-0016-0001-534150_F03.jpg
case_images: F3
case_images: His eosinophil count decreased and his respiratory symptoms disappeared (Fig. 3).
case_images: PMC10601777_02
case_images: a Timeline of events in Case 1. b Timeline of events in Case 2.
case_images: cro-2023-0016-0001-534150_F01.jpg
case_images: PMC10601777_02_cro-2023-0016-0001-534150_F01.jpg
case_images: F1
case_images: Since April 2022, he experienced nocturnal cough, dyspnea, and wheezing (Fig. 1b).